334 results
Page 4 of 17
8-K
EX-10.1
at2vermd
30 Mar 23
Form of Parent Stockholder Support Agreement
8:50am
8-K
EX-99.2
6iazs99org6b
30 Mar 23
Form of Parent Stockholder Support Agreement
8:50am
DEFA14A
e2bv6hb3i5n17kdk
16 Dec 22
Additional proxy soliciting materials
5:16pm
8-K
EX-99.1
9cz3q4djugs0j0vvzp
16 Dec 22
Diffusion Pharmaceuticals Announces Agreement with LifeSci Special Opportunities
5:10pm
8-K
EX-10.1
e3digozj
16 Dec 22
Diffusion Pharmaceuticals Announces Agreement with LifeSci Special Opportunities
5:10pm
PRRN14A
kj8y9
6 Dec 22
Revised preliminary proxy statement filed by non-management
8:30am
DEFA14A
EX-99.1
upz4us4wxaa fz9wszj
5 Dec 22
Additional proxy soliciting materials
9:59pm
8-K
EX-99.1
njo46h9p w41w
5 Dec 22
Diffusion has a highly engaged and independent board that possesses the right skills and experience to execute the strategic review process
9:58pm
DEFC14A
asy1y
5 Dec 22
Proxy in contested solicitation
5:12pm
PRRN14A
mgso2nhkjkkzyb7d
2 Dec 22
Revised preliminary proxy statement filed by non-management
2:36pm
PRER14A
t9y6rv1c7 xiajd
28 Nov 22
Preliminary revised proxy
5:17pm
PREC14A
ab750fww
23 Nov 22
Preliminary proxy with contested solicitation
11:26am
PREC14A
ib264bujevyuvaxgc1z
18 Nov 22
Preliminary proxy with contested solicitation
5:08pm
8-K
EX-99.1
pr1ri2do67oyl
18 Nov 22
Diffusion Pharmaceuticals Sees Significant Progress in its Strategic Review Process
4:40pm
DEFA14A
EX-99.1
c4is hruyzz
14 Nov 22
Additional proxy soliciting materials
7:41am
8-K
EX-99.1
9rhe1ctkntw 924h
14 Nov 22
Diffusion Pharmaceuticals Sees Significant Progress in its Strategic Review Process
7:40am
8-K
EX-99.1
p0dra
27 Oct 22
Diffusion Pharmaceuticals Announces Strategic Review Process to Evaluate Value-Enhancing Alternatives including Opportunities to Better Leverage TSC
4:15pm
8-K
EX-99.1
6kw33 60qg5vt
16 Aug 22
Diffusion Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
4:21pm